Trial intelligence / Profile preview

PK Interaction of Ramipril and Sotagliflozin in Healthy Subjects

NCT03414723Phase 1Completed

Sponsor
Sanofi
Start
Jan 2018
Primary completion
Mar 2018
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, open-label, single-arm trial of sotagliflozin in diabetes mellitus (DM), sponsored by Sanofi. Primary endpoint: Area under the plasma concentration versus time curve during a dosing interval. Started Jan 2018; status: completed.

02

Drugs

sotagliflozin
03

Conditions

diabetes mellitus (DM)

Beyond the preview

Go deeper on NCT03414723.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03414723.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call